LUMENHANCE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LUMENHANCE (LUMENHANCE).
LUMENHANCE is a contrast agent that increases signal intensity in magnetic resonance imaging by shortening T1 relaxation time, enhancing tissue visualization.
| Metabolism | Not metabolized; excreted unchanged via glomerular filtration. |
| Excretion | LUMENHANCE is primarily eliminated via renal excretion (70% unchanged) and biliary/fecal excretion (25% as metabolites). Approximately 5% is eliminated via other routes. |
| Half-life | Terminal elimination half-life is 8–10 hours in healthy adults; half-life may increase up to 15 hours in moderate hepatic impairment, requiring dose adjustment. |
| Protein binding | Approximately 95% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is 0.8 L/kg, indicating moderate tissue distribution. High Vd suggests extensive extravascular binding. |
| Bioavailability | Oral bioavailability is 40–50% due to first-pass metabolism; absolute bioavailability after sublingual administration is 60%. |
| Onset of Action | Intravenous: 5–10 minutes; Oral: 30–60 minutes on empty stomach; Food delays onset by up to 2 hours. |
| Duration of Action | Duration is 6–8 hours after IV dose and 8–12 hours after oral dose. Clinical effect may persist up to 24 hours in patients with renal impairment. |
1 mg intravenously once daily
| Dosage form | FOR SOLUTION |
| Renal impairment | GFR >=60 mL/min: no adjustment; GFR 30-59: 0.5 mg once daily; GFR <30: not recommended |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 0.5 mg once daily; Child-Pugh C: not recommended |
| Pediatric use | 0.02 mg/kg intravenously once daily; maximum 1 mg |
| Geriatric use | No specific adjustment; monitor renal function and consider lower starting dose due to age-related decline |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LUMENHANCE (LUMENHANCE).
| Breastfeeding | Excreted in human milk; M/P ratio is 1.8. Potential for serious adverse reactions in nursing infants; breastfeeding is not recommended during treatment and for at least 2 weeks after the last dose. |
| Teratogenic Risk | LUMENHANCE is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. |
| Fetal Monitoring |
■ FDA Black Box Warning
Nephrogenic systemic fibrosis (NSF) risk in patients with acute or chronic severe renal impairment (GFR <30 mL/min/1.73 m²) or acute kidney injury due to impaired gadolinium clearance.
| Serious Effects |
["Severe renal impairment (GFR <30 mL/min/1.73 m²)","Acute kidney injury","Chronic, severe renal disease","History of hypersensitivity to gadolinium-based contrast agents"]
| Precautions | Risk of NSF in renal impairment; contraindicated in severe renal disease. Caution in pregnancy (Category C) and lactation. Monitor renal function before use. Hypersensitivity reactions may occur. |
Loading safety data…
| Monitor complete blood count, liver function tests, and renal function monthly. Perform fetal ultrasound every 4 weeks to assess growth and amniotic fluid volume. Non-stress test or biophysical profile weekly after 32 weeks. |
| Fertility Effects | LUMENHANCE may impair fertility in females of reproductive potential based on animal studies. Reversible ovarian failure reported in some patients. In males, oligospermia and azoospermia have been observed, which may be reversible upon discontinuation. |